Background Previous studies have independently validated the prognostic relevance of
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from …

Introduction The Residual Cancer Burden (RCB) quantifies residual disease after
neoadjuvant chemotherapy (NAC). Its predictive value has not been validated on large …

Background: Recent studies have demonstrated independent validation of the prognostic
relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. However, a …

Importance Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in
breast cancer strongly correlates with overall survival and has become the standard end …

Although identified to be at a higher risk of relapse, no consensus exists on the treatment of
breast cancer (BC) patients with no pathological complete response after neoadjuvant …

Simple Summary The disparities in ovarian cancer care and outcomes have been linked to
socioeconomic indicators. Our study mainly demonstrated that women living in economically …

PURPOSE To apply text mining (TM) technology on electronic medical records (EMRs) of
patients with breast cancer (BC) to retrieve the occurrence of a pregnancy after BC …

PURPOSE The treatment of breast cancer, the leading cause of cancer and cancer mortality
among women worldwide, is mainly on the basis of surgery. In this study, we describe the …

Highlights•Quality assurance is poorly reported in most surgical randomized trials.•Quality
assurance should be better integrated in surgical trial design, with strict compliance to the …

Background Residual Cancer Burden (RCB) after neoadjuvant chemotherapy (NAC) has
been validated to predict event-free survival (EFS) across breast cancer subtypes but its …